Introduction {#s1}
============

Limb-girdle muscular dystrophy type 2A (LGMD2A) is a recessive genetic disorder caused by mutations in calpain 3 (CAPN3), a muscle-specific, calcium-dependent cystein protease. Calpain 3 structure is similar to that of the ubiquitous calpains 1 and 2, but calpain 3 has specific regions (NS, IS1, and IS2) that confer it special characteristics such as autocatalytic and nuclear translocation capacity. Although calpain 3 was identified in 1989 [@pone.0003750-Sorimachi1], little is known about its function or its *in vivo* substrates. It has been reported to play different roles in the cell. Calpain 3 has a certain role in direct and indirect regulation of conventional calpains by proteolytic degradation of calpains and calpastatin respectively [@pone.0003750-Ono1]. It may be involved in muscle contraction due to its link to titin and to its regulation by calcium [@pone.0003750-Kinbara1]--[@pone.0003750-Hayashi1].

Calpain 3 was shown to be in complex with dysferlin, suggesting a membrane homeostasis role of calpain 3 [@pone.0003750-Huang1], and more recent studies demonstrated that AHNAK, a novel component of the dysferlin protein complex, serves as a direct substrate of calpain 3 in cell culture [@pone.0003750-Huang2].

On the other hand, it has been confirmed that calpain 3 can cleave the C-terminal portion of FLNC *in vitro* and suggested that FLNC may be an *in vivo* substrate for calpain 3, functioning to regulate protein-protein interactions with sarcoglycans. Thus, calpain-mediated remodeling of cytoskeletal-membrane interactions, such as those occurring during myoblast fusion and muscle repair, may involve regulation of FLNC-sarcoglycan interactions [@pone.0003750-Guyon1].

Its presence in the nucleus has led to suggest that calpain 3 plays an important role in regulation of transcription factors indirectly controlling apoptotic processes [@pone.0003750-Baghdiguian1], [@pone.0003750-Baghdiguian2]. Recent studies reported that the antiapoptotic factor, cellular FLICE inhibitory protein (c-FLIP), is NF-κB dependent and is only expressed when CAPN3 is present [@pone.0003750-Benayoun1]. However, other studies suggest that apoptosis may be secondary to muscle damage and inflammatory response [@pone.0003750-Kramerova1].

Based on the observation of the C3 knockout (C3KO) mice, it has been suggested that calpain 3 is necessary for ubiquitination and acts upstream of the ubiquitination machinery [@pone.0003750-Kramerova2].

Inflammatory cells have been detected in muscle tissue from patients with mutations in the CAPN3 gene in early stages [@pone.0003750-Krahn1] as happen in other distrophies. The role of inflammation in many dystrophies seems to be unexplained, and it has been related to the presence of signaling factors (cytokines) that withstand inflammatory mechanisms and regulatory phenomena [@pone.0003750-Arahata1]--[@pone.0003750-Gallardo1].

In this study, the RNA expression profiling in muscle from biopsies of LGMD2A patients and control subjects were compared in order to determine the potential functions and the pathways in which calpain 3 is implicated.

Materials and Methods {#s2}
=====================

Muscle samples and RNA processing {#s2a}
---------------------------------

Muscle biopsies were taken from 10 LGMD2A patients (3 females and 7 males aged 13--48 years, mean age 29,5 years) and 10 controls (2 females and 8 males aged 22--84 years, mean age 50,2 years). Two out of the 10 LGMD2A patients showed an inflammatory pattern with eosinophilic infiltrates in their biopsies.

For diagnostic purposes deltoid, quadriceps, and biceps muscle specimens were collected using institutionally approved protocols and after obtaining informed consent ([Table 1](#pone-0003750-t001){ref-type="table"}). Muscle tissues were snap frozen and stored at −80°C. Most of the 7 symptomatic cases showed similar necrosis and regenerating phenomena (data not available in one case).
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###### Distribution of muscle biopsies taken from 10 LGMD2A patients and 10 control subjects.

![](pone.0003750.t001){#pone-0003750-t001-1}

  Biopsy Number    Status    Gender        Muscle         Age                                                                                                                   Myopathological data                                                                                                                   Gardner-Medwin-Walton Scale    CAPN3 mutations    
  --------------- --------- -------- ------------------- ----- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------- -------------------- --------------------
  EXP-01           LGMD2A      M         Quadriceps       34                                                         Mild myopathic changes (fiber size alteration, centrally located nuclei and splitting) No necrosis, no regeneration, no lobulated fibers.                                                                      2                  p.(Gly222Arg)        p.(Arg748Gln)
  EXP-02           LGMD2A      F           Deltoid        33                                                                                                            Necrosis and regenerating phenomena                                                                                                                         3                   c.946-1G\>A         p.(Gln660Arg)
  EXP-03           LGMD2A      M         Quadriceps       37                                                                                                       Necrosis, regenerating phenomena and fibrosis                                                                                                                 Unknown               p.(Met248Arg)        p.(Arg769Gln)
  EXP-04           LGMD2A      M         Quadriceps       44                                                                                                            Necrosis and regenerating phenomena                                                                                                                      Unknown                p.(Gln300X)         p.(Gln660Arg)
  EXP-05           LGMD2A      M           Deltoid        13    Inflammatory reaction around necrotic and non necrotic fibers. Inflammation collects at endomysial site sometimes with perivascular infiltrate without destruction of walls of arterioles and venules. Numerous eosinophilic leucocytes are present.          Asymptomatic           p.(Arg788SerfsX14)   p.(Arg788SerfsX14)
  EXP-09           LGMD2A      F      Biceps braquialis   14                            Myositis with local infiltration of eosinophils. Patchy, focal inflammatory cell infiltrate with minor changes in the architecture of fibers without changes in the distribution of the fiber type.                                   Asymptomatic             p.(Arg490Trp)      p.(Gly691TrpfsX7)
  EXP-35           LGMD2A      M           Deltoid        48                                                                                                            Necrosis, fibrosis, lobulated fibres                                                                                                                        7                   p.(Gln142X)          p.(Gln142X)
  EXP-36           LGMD2A      M         Quadriceps       26                                                                                                            Necrosis and regenerating phenomena                                                                                                                         2                  p.(Lys254Glu)          c.1910delC
  EXP-40           LGMD2A      M         Quadriceps       29                                                                                               Mild myopathic changes (centrally located nuclei and fibrosis)                                                                                                           7                  p.(Ala160Gly)         c.1029+3A\>G
  EXP-41           LGMD2A      F           Deltoid        17                                                                                                                     No data available                                                                                                                                  2                c.2185-12_2194del    p.(Arg788SerfsX14)
  EXP-25           Control     F           Deltoid        57                                                                                                                                                                                                                                                                                                             
  EXP-27           Control     M         Quadriceps       50                                                                                                                                                                                                                                                                                                             
  EXP-28           Control     M         Quadriceps       22                                                                                                                                                                                                                                                                                                             
  EXP -29          Control     F         Quadriceps       73                                                                                                                                                                                                                                                                                                             
  EXP -30          Control     M         Quadriceps       84                                                                                                                                                                                                                                                                                                             
  EXP-31           Control     M         Quadriceps       46                                                                                                                                                                                                                                                                                                             
  EXP-32           Control     M         Quadriceps       48                                                                                                                                                                                                                                                                                                             
  EXP-33           Control     M           Deltoid        51                                                                                                                                                                                                                                                                                                             
  EXP-38           Control     M         Quadriceps       31                                                                                                                                                                                                                                                                                                             
  EXP-39           Control     M         Quadriceps       41                                                                                                                                                                                                                                                                                                             

The quality of all RNAs obtained from muscle biopsies (RNAPlus, QBiogene) was verified using spectrophotometry and the Bioanalyzer system (Agilent). All of them showed acceptable quality and integrity (RIN above 7) to be eligible for the experiment.

All RNAs were reverse-transcribed, and biotinylated cRNA probes were generated by *in vitro* transcription (Ambion, CA, USA). Fragmented cRNA of each sample was hybridized individually to human HG-U133A (22.283 probe sets) and HG-U133B (22.645 probe sets) GeneChips (Affymetrix, Santa Clara, California) in order to analyze the expression of 44.928 probes, comprising more than 33.000 genes.

Data analysis {#s2b}
-------------

In-depth quality controls were performed to analyze the validity of the hybridization processes in accordance with four criteria. First, the correct presence of the signal corresponding to the spike control BioB. Second, the expression ratio between the 3′ and 5′ ends of the housekeeping GAPDH should not exceed a value of three. Third, the full percentage of presences detected by the Affymetrix Detection algorithm for each array must be in the range 40--60. And finally, the percentage of outlier probe sets detected within each microarray should be less than 5%. All hybridized arrays on the study met all four quality criteria, demonstrating the reliability of data generated.

The hybridized arrays were scanned, and raw data were extracted using the Microarray Analysis Suite 5.0 (MAS5; Affymetrix). The raw data were normalized using RMA (Robust Multichip Average) expression summary in Bioconductor [@pone.0003750-Gentleman1]. RMA consists of three steps: a background adjustment, quantile normalization, and finally summarization [@pone.0003750-Irizarry1]--[@pone.0003750-Bolstad1].

The sensitivity of microarray-generated data to noise from experimental variables is well documented [@pone.0003750-Haslett1]. For the analysis, the average values of each tested group (patients and controls) were used in order to obtain the most homogeneous results, trying to avoid variability between individual cases due to different characteristics (genetic background, sex, age, muscles, mutations, etc.). Two statistical methods were applied in order to distinguish significant and substantial differential expression from noise and variation due to either genetic heterogeneity or experimental procedures.

First, in order to identify significantly different genes between LGMD2A patients and normal controls, a geometric fold-change analysis was used [@pone.0003750-Haslett1], [@pone.0003750-Bakay1]. The threshold was set at a two-fold change value. Using the criterion of fold-change implies that larger fold changes are most likely to be real and no hypothesis is assumed. Principal component analysis (PCA) was performed after array normalization. PCA is a technique that summarizes a large set of variables in a smaller set that retains the essential variance of the original data set [@pone.0003750-Duda1]. PCA derives an equivalent, uncorrelated set of new variables from the original set of correlated variables according to their contribution to a ranked set of principal components [@pone.0003750-Kang1].

Second, Class Comparison Difference Analyses were performed using BRB-ArrayTools developed by Dr. Richard Simon and BRB-ArrayTools Development Team. In order to identify probe sets with significant intensity differences between disease classes, a two-sample univariate *t*-test was applied to the unaffected control data set vs. the LGMD2A data set. The use of p-values implies hypothesis testing. It is assumed in the null hypothesis that there is no fold change and then evidence was looked for to reject it using a type-1 error. The threshold was set at p 0.001.

To minimize false positives, only the probe sets commonly yielded by both methodologies were included into the final list of genes differentially expressed in LGMD2A.

Moreover, as an additional supporting process, two machine learning feature selection techniques were run. Symmetrical uncertainty ranking [@pone.0003750-Wang1] was first applied as an univariate criterion to measure the worth of each probe set alone: this computes the mutual information with respect to the class phenotype and compensates for the bias of the information gain. Correlation-based Feature Subset (CFS) selection [@pone.0003750-Hall1], a multivariate feature selection that evaluates the merit of a probe set subset by measuring the individual predictive power of each probe set along with the redundancy within that subset, was then used. CFS outputs a subset of features instead of individual relevances.

The same procedure was used to compare samples from patients who were asymptomatic but had eosinophilic infiltrates in their muscle biopsies (2 cases) and samples from healthy controls (10 cases).

Microarray data have been submitted to the GEO (Gene Expression Omnibus) public database (accession GSE11681).

Quantitative Real-Time PCR {#s2c}
--------------------------

To investigate the validity of array data, expression levels of the differentially expressed genes were measured using the TaqMan quantitative RT-PCR assay. Relative expression levels initially determined with the cDNA microarrays were correlated to the expression levels assessed using quantitative RT-PCR for each patient sample.

Whereas microarrays identify target genes of interest among thousands of genes, truly quantitative information relies on quantitative RT-PCR. Some of the significantly regulated changes found on the microarray could be replicated by quantitative RT-PCR. Quantitative RT-PCR was performed using the 7900 HT Fast Real-Time PCR System (Applied Biosystems). Because of the limiting RNA amount isolated from muscle biopsies used for microarray analysis, only a few samples (6 cases) were used for confirmation with quantitative RT-PCR experiments.

The TaqMan Low Density Arrays (TLDA) were purchased from Applied Biosystems, and the protocol recommended by the manufacturer was used. Customer-designed TLDAs were used in order to test a series of 63 genes. In order to select these genes, genes with unknown function, hypothetical proteins, and open reading frame regions were excluded. Gene families were represented including only some of the members, such as collagens, etc. Moreover, genes showing differential expression profiling in the comparison between patients with eosinophilic infiltrates and healthy controls were included in the TLDA, as well as genes with expression variation in other studies.

Expression levels for all transcripts were determined relative to the internal housekeeping control gene GAPDH in the TLDAs which, as expected, did not demonstrate altered expression according to microarray analysis.

In order to identify probe sets with significant intensity differences, the method applied to the unaffected control data set vs. the LGMD2A data set was Benjamini-Hochberg method using Stat Miner program (Integromics).

Results {#s3}
=======

After having adjusted the background, normalized and summarized the data, the fold change obtained generates a list by magnitude of response. As a result of this method, the fold change analysis identified 156 differentially expressed probe sets in LGMD2A skeletal muscle compared to control skeletal muscle. Of these, 92 were significantly overexpressed and 64 showed a reduced expression in LGMD2A patients compared to the unaffected controls.

PCA grouped together on the one hand patient samples and on the other hand control samples and a greater variability was seen among controls due to the heterogeneity of this group ([Figure 1](#pone-0003750-g001){ref-type="fig"}).

![Principal component analysis (PCA) of HG-U133A microarrays (A) and of HG-U133B microarrays (B) after normalization.\
P: LGMD2A Patients. C: Healthy controls. Muscle specimens obtained from individuals of the same status showed the greatest similarities.](pone.0003750.g001){#pone-0003750-g001}

On the other hand, the additional statistical method used to analyze the data, the Class Comparison Differences method, applied a two-sample univariate *t*-test to the unaffected control data set vs. the LGMD2A data set. This method identified 627 probe sets with a p value higher than 0.001.

However, the final list of genes comprised 86 probe sets (74 genes) commonly yielded by the two methodologies which were differentially expressed in LGMD2A compared to unaffected muscle biopsies. Of these 74 genes, 53 were overexpressed and 21 had a reduced expression in the LGMD2A patients and all the genes were clustered into functional groups ([Table 2](#pone-0003750-t002){ref-type="table"}). Transcripts were classified according to different biological processes, as obtained from LocusLink ([www.ncbi.nlm.nih.gov/LocusLink/](http://www.ncbi.nlm.nih.gov/LocusLink/)): extracellular matrix proteins/phosphate transport, cell adhesion, muscle development, transcription factors, signaling pathways, metabolic process, transport, ubiquitin cycle, and other functions.

10.1371/journal.pone.0003750.t002

###### Significantly differentially regulated transcripts, NV: Not validated by TLDAs.

![](pone.0003750.t002){#pone-0003750-t002-2}

  Affymetrix ID                                                       Biological process/Gene title                                                     Gene symbol                  Fold change   Parametric p value Class Comparison   Fold change Validated by RT-PCR   Significant p value Stat Miner
  ------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------- ------------- ------------------------------------- --------------------------------- --------------------------------
  Extracellular matrix proteins                                                                                                                                                                                                                                           
  202310_s\_at                                                          collagen, type I, alpha 1                                         COL1A1[\*](#nt101){ref-type="table-fn"}       4.71                    0.0003482                             5.86                          0.012178774
  202404_s\_at                                                          collagen, type I, alpha 2                                         COL1A2[\*](#nt101){ref-type="table-fn"}       4.72                    6.61e-05                               NV                                --
  211161_s\_at                                                         collagen, type III, alpha 1                                        COL3A1[\*](#nt101){ref-type="table-fn"}       7.72                     1.1e-06                              13.71                              --
  201852_x\_at                                                                                                                                                                          5.12                     7.4e-06                                                  
  215076_s\_at                                                                                                                                                                          4.79                    3.48e-05                                                  
  212488_at                                                             collagen, type V, alpha 1                                                         COL5A1                        2.07                    8.18e-05                              9.24                            1.13E-04
  221729_at                                                             collagen, type V, alpha 2                                                         COL5A2                        3.12                     \<1e-07                               NV                                --
  221730_at                                                                                                                                                                             2.12                      3e-07                                                   
  203477_at                                                            collagen, type XV, alpha 1                                        COL15A1[\*](#nt101){ref-type="table-fn"}       2.80                    2.36e-05                               NV                                --
  225681_at                                                     collagen triple helix repeat containing 1                                                 CTHRC1                        2.96                    3.74e-05                               NV                                --
  Cell adhesion                                                                                                                                                                                                                                                           
  201005_at                                                                 CD9 antigen (p24)                                              CD9 [\*](#nt101){ref-type="table-fn"}        2.38                    6.36e-05                              2.16                            5.71E-02
  212063_at                                           CD44 antigen (homing function and Indian blood group system)                        CD44 [\*](#nt101){ref-type="table-fn"}        2.35                    0.0002703                             2.23                           0.3071496
  211719_x\_at                                                                fibronectin 1                                                FN1[\*](#nt101){ref-type="table-fn"}         2.33                    0.0006326                             3.30                            1.16E-02
  210495_x\_at                                                                                                                                                                          2.30                    0.0001008                                                 
  216442_x\_at                                                                                                                                                                          2.21                    0.0001307                                                 
  Muscle development                                                                                                                                                                                                                                                      
  205940_at                                              myosin, heavy polypeptide 3, skeletal muscle, embryonic                           MYH3[\*](#nt101){ref-type="table-fn"}        11.78                    1.4e-06                              40.62                           2.15E-04
  205145_s\_at                                                   myosin, light polypeptide 5, regulatory                                                   MYL5                         4.28                    3.49e-05                              7.21                            1.83E-02
  204173_at                                                            myosin light chain 1 slow a                                                   MLC1SA ( = MYL6B)                  2.41                    0.0003024                             3.28                            1.77E-02
  219829_at                                                    integrin beta 1 binding protein (melusin) 2                                               ITGB1BP2                       2.23                     1.3e-06                              2.50                          0.013391304
  Transcription factors                                                                                                                                                                                                                                                   
  202431_s\_at                                            v-myc myelocytomatosis viral oncogene homolog (avian)                            MYC[\*](#nt101){ref-type="table-fn"}         0.48                    0.0006587                             0.35                               --
  201466_s\_at                                               v-jun sarcoma virus 17 oncogene homolog (avian)                               JUN[\*](#nt101){ref-type="table-fn"}         0.47                    4.98e-05                              0.69                          0.443749559
  219990_at                                                            E2F transcription factor 8                                                          E2F8                         3.22                    0.0001105                             4.52                            4.80E-03
  201473_at                                                               jun B proto-oncogene                                             JUNB[\*](#nt101){ref-type="table-fn"}        0.41                    0.0002329                              NV                                --
  209189_at                                               v-fos FBJ murine osteosarcoma viral oncogene homolog                             FOS[\*](#nt101){ref-type="table-fn"}         0.12                    7.52e-05                              0.10                               --
  203973_s\_at                                                CCAAT/enhancer binding protein (C/EBP), delta                               CEBPD[\*](#nt101){ref-type="table-fn"}        0.39                    0.0009174                             1.61                          0.266597408
  201694_s\_at                                                           early growth response 1                                           EGR1[\*](#nt101){ref-type="table-fn"}        0.31                    5.16e-05                              0.13                            1.74E-03
  227404_s\_at                                                                                                                                                                          0.12                    8.11e-05                                                  
  209357_at                                 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2                             CITED2                        0.39                      9e-07                               0.57                          0.255171653
  210479_s\_at                                                        RAR-related orphan receptor A                                                        RORA                         0.46                    0.0003675                              NV                                --
  202393_s\_at                                                           Kruppel-like factor 10                                                            KLF10                        0.45                    0.0000651                             0.49                          0.130862236
  221778_at                                                                 KIAA1718 protein                                                         KIAA1718 (JHDM1D)                  0.48                    0.0009927                              NV                                --
  Signal transduction                                                                                                                                                                                                                                                     
  209541_at                                                   insulin-like growth factor 1 (somatomedin C)                                 IGF1[\*](#nt101){ref-type="table-fn"}        2.81                      1e-07                               1.96                            7.01E-02
  209822_s\_at                                                    very low density lipoprotein receptor                                   VLDLR[\*](#nt101){ref-type="table-fn"}        2.63                      3e-07                                NV                                --
  213880_at                                            leucine-rich repeat-containing G protein-coupled receptor 5                                         LGR5                         0.30                    0.0004577                             0.23                            6.35E-02
  219654_at                                protein tyrosine phosphatase-like (proline instead of catalytic arginine), member a                             PTPLA                        2.42                    4.83e-05                               NV                                --
  222918_at                                                         RAB9B, member RAS oncogene family                                                      RAB9B                        2.04                    1.09e-05                               NV                                --
  212099_at                                                         ras homolog gene family, member B                                                      RHOB                         0.41                    0.0000594                              NV                                --
  217728_at                                                    S100 calcium binding protein A6 (calcyclin)                                S100A6[\*](#nt101){ref-type="table-fn"}       2.26                    0.0008602                             2.43                            5.00E-02
  Signal pathways                                                                                                                                                                                                                                                         
  200665_s\_at                                            secreted protein, acidic, cysteine-rich (osteonectin)                           SPARC[\*](#nt101){ref-type="table-fn"}        2.02                    0.000903                              2.55                            5.82E-02
  218087_s\_a                                                      sorbin and SH3 domain containing 1                                                     SORBS1                        2.05                    0.000123                               NV                                --
  214844_s\_at                                                              docking protein 5                                                              DOK5                         2.24                    3.16e-05                              3.16                            6.09E-03
  203697_at                                                             frizzled-related protein                                                           FRZB                         5.42                    0.000466                              13.16                           2.41E-04
  203698_s\_at                                                                                                                                                                          2.99                    0.000466                                                  
  203789_s\_at                           sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C                           SEMA3C                        2.86                    0.0001054                              NV                                --
  201309_x\_at                                                     chromosome 5 open reading frame 13                                                     C5orf13                       2.09                    0.0005666                              NV                                --
  236860_at                                                      Neuropeptide Y receptor Y6 (pseudogene)                                                   NPY6R                        4.09                    0.0007927                              NV                                --
  Metabolic process                                                                                                                                                                                                                                                       
  201425_at                                                  aldehyde dehydrogenase 2 family (mitochondrial)                                               ALDH2                        0.43                    8.62e-05                              0.67                          0.459523739
  209301_at                                                               carbonic anhydrase II                                            CA2[\*](#nt101){ref-type="table-fn"}         0.48                    0.0007153                             0.79                          0.522535838
  202464_s\_at                                            6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3                                           PFKFB3                        0.15                     1.5e-06                              0.45                          0.141846652
  Transport                                                                                                                                                                                                                                                               
  208691_at                                                         transferrin receptor (p90, CD71)                                       TFRC[\*](#nt101){ref-type="table-fn"}        8.11                    6.47e-05                              4.52                            4.80E-03
  207332_s\_at                                                                                                                                                                          5.99                    6.28e-05                                                  
  204430_s\_at                                solute carrier family 2 (facilitated glucose/fructose transporter), member 5                                SLC2A5                        2.17                    0.0003736                             3.74                            2.69E-03
  201560_at                                                         chloride intracellular channel 4                                                       CLIC4                        2.20                    0.0001832                              NV                                --
  202236_s\_at                                    solute carrier family 16 (monocarboxylic acid transporters), member 1                                   SLC16A1                       2.55                     \<1e-07                               NV                                --
  205073_at                                               Cytochrome P450, family 2, subfamily J, polypeptide 2                                           CYP2J2                        2.04                     3.4e-05                               NV                                --
  224579_at                                                        Solute carrier family 38, member 1                                                     SLC38A1                       2.58                    0.0007761                              NV                                --
  219525_at                                                           hypothetical protein FLJ10847                                                 FLJ10847 (SLC47A1)                  0.47                    6.42e-05                               NV                                --
  217966_s\_at                                                     chromosome 1 open reading frame 24                                                C1orf24 (FAM129A)                  0.47                     0.00045                              0.78                           0.55888133
  Ubiquitin cycle                                                                                                                                                                                                                                                         
  218306_s\_at                     hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1                     HERC1                        2.22                    0.0000045                             2.45                            2.29E-02
  218575_at                                                       Anaphase promoting complex subunit 1                                                    ANAPC1                        2.02                      9e-07                               1.31                          0.447268323
  229267_at                                                                                                                                                                             2.07                    0.0001629                                                 
  Other functions                                                                                                                                                                                                                                                         
  218273_s\_at                               protein phosphatase 2C, magnesium-dependent, catalytic subunit (mitochondrial)                                PPM2C                        2.49                    1.55e-05                              3.08                            2.97E-02
  201609_x\_at                                                isoprenylcysteine carboxyl methyltransferase                                 ICMT[\*](#nt101){ref-type="table-fn"}        2.25                     7.2e-06                               NV                                --
  201611_s\_at                                                                                                                                                                          2.00                    1.88e-05                                                  
  202965_s\_at                                                                  calpain 6                                                                  CAPN6                        2.05                    1.71e-05                              5.31                            9.12E-04
  212848_s\_at                                                      chromosome 9 open reading frame 3                                                     C9orf3                        2.01                    0.0003013                              NV                                --
  201010_s\_at                                                       Thioredoxin interacting protein                                      TXNIP[\*](#nt101){ref-type="table-fn"}        0.43                      1e-05                               0.49                          0.133790906
  201009_s\_at                                                                                                                                                                          0.42                    0.0009904                                                 
  202917_s\_at                                               S100 calcium binding protein A8 (calgranulin A)                                              S100A8                        0.34                    0.0002179                             0.27                            1.51E-02
  209398_at                                                                  histone 1, H1c                                                              HIST1H1C                       0.45                    0.0003089                             0.76                          0.491015255
  225061_at                                                    DnaJ (Hsp40) homolog, subfamily A, member 4                                DNAJA4[\*](#nt101){ref-type="table-fn"}       2.53                    0.0000529                             3.65                            8.54E-03
  209596_at                                                          matrix-remodelling associated 5                                                       MXRA5                        2.90                      5e-07                                NV                                --
  219087_at                                                               asporin (LRR class 1)                                                            ASPN                         4.58                      4e-07                                NV                                --
  235022_at                                                        chromosome 18 open reading frame 19                                                   C18orf19                       2.34                      1e-07                                NV                                --
  218820_at                                                       chromosome 14 open reading frame 132                                                   C14orf132                      2.14                    2.87e-05                               NV                                --
  202016_at                                                   mesoderm specific transcript homolog (mouse)                                                 MEST                         2.11                    0.000709                               NV                                --
  218999_at                                                           hypothetical protein FLJ11000                                                 FLJ11000 (TMEM140)                  0.49                    218999_at                              NV                                --
  224836_at                                                   tumor protein p53 inducible nuclear protein 2                              TP53INP2[\*](#nt101){ref-type="table-fn"}      2.46                    0.0003853                              NV                                --
  Unknown function                                                                                                                                                                                                                                                        
  238124_at                                                             Myomesin family, member 3                                                          MYOM3                        2.30                    0.0000126                             6.74                            1.86E-04
  230284_at                                                                                                                                                                             2.01                    0.0000003                                                 
  202759_s\_at                                                             PALM2-AKAP2 protein                                                          PALM2-AKAP2                     2.16                    0.0000007                              NV                                --
  229778_at                                                           Hypothetical protein MGC10946                                                 MGC10946 (C12orf39)                 2.75                    0.0000022                              NV                                --
  211071_s\_at                       myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11                      MLLT11                        3.92                    0.0002385                              NV                                --
  218876_at                                                              brain specific protein                                                       CGI-38 (TPPP3)                    2.86                    0.0000867                              NV                                --
  221104_s\_at                                                       nipsnap homolog 3B (C, elegans)                                                     NIPSNAP3B                      2.68                    0.0001963                              NV                                --
  225242_s\_at                                                          steroid sensitive gene 1                                                       URB (CCDC80)                     3.22                    0.0004132                              NV                                --

Dysregulated genes in FSHD, DMD, α-sarcoglycan, and congenital myopathies (Campanaro et al 2002, Winokur et al 2003, Haslett et al 2003, Taniguchi et al 2006, Osborne et al 2007).

The additional supporting process, the Correlation-based Feature Subset selection (CFS) [@pone.0003750-Hall1] highlighted a set of 21 genes. Of these 21 genes, 7 corresponded to the previously determined group of 74 genes. In turn, Symmetrical Uncertainty Ranking returned correlation coefficients higher than 0.5 for 24 genes within the list. Note that the highest correlation was 0.816 when the coefficient was constrained between 1 (maximum) and 0 (minimum). The average coefficient for the whole gene list was 0.36, with a standard deviation of 0.177.

Overview of expression profiling in LGMD2A muscles {#s3a}
--------------------------------------------------

Some transcript classes were of particular interest in this analysis ([Table 2](#pone-0003750-t002){ref-type="table"}). Most genes found to be dysregulated in LGMD2A were genes grouped in the transcription factor category, and some of them showed the lowest fold-change values obtained in the study (FOS, EGR1). By contrast, genes showing the highest fold-change values included extracellular matrix proteins, genes involved in muscle development, and three additional genes with different functions (FRZB, TFRC, and CAPN6).

As a whole, in most of the biologically classified processes, the same trend to up- or downregulation was seen for all genes involved in the same process. Genes associated with extracellular matrix (collagen types I, III, V, and XV, and SPARC), cell adhesion, muscle development (MYH3, MYL5 and ITGB1BP2), signaling pathways, and ubiquitin cycle predominated among upregulated genes. However, all genes involved in metabolic processes and transcription factors (except for the E2F8 gene) were downregulated ([Table 2](#pone-0003750-t002){ref-type="table"}).

On the other hand, upregulation of IGF1, which is a regulator of somatic growth and cell proliferation, was seen in this study. IGFa is an inducer of different pathways such as the phosphatidylinositol 3-kinase survival (through activation of AKT1, AKT2), the calcineurin.mediated signaling pathways, and of GATA2 activation.

HERC1 and ANAPC1 are genes implicated in the ubiquitin cycle and showed upregulation in LGMD2A muscle samples. HERC1, ubiquitously expressed, is located in the cytosol in the Golgi apparatus, stimulating guanine nucleotide, forming a cytosolic ternary complex with clathrin and Hsp70, and is involved in protein trafficking. ANAPC1 is a component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle.

There are two deregulated genes according to our results whose cell location is the mitochondrion matrix, one of which is involved in the metabolic process, ALDH2 (aldehyde dehydrogenase 2 family) (downregulated), while the other, the PPM2C gene (protein phosphatase 2C, magnesium-dependent, catalytic subunit) (upregulated) is implicated in protein amino acid dephosphorylation.

Expression changes in common with other muscular dystrophies {#s3b}
------------------------------------------------------------

Twenty four out of the 74 deregulated genes with altered expression in LGMD2A were also deregulated in other muscular dystrophies (DMD, α-SGD, FSHD, dysferlinopathies, Fukuyama-type congenital muscular dystrophy, and laminin-α2 deficient congenital muscular dystrophy) [@pone.0003750-Haslett1], [@pone.0003750-Chen1]--[@pone.0003750-Osborne1] ([Table 2](#pone-0003750-t002){ref-type="table"}).

LGMD2A and eosinophil infiltration {#s3c}
----------------------------------

A comparison was made between biopsies of control muscles (10 cases) and biopsies from two cases showing eosinophil infiltrates. Results of this comparison are summarized in [Table 3](#pone-0003750-t003){ref-type="table"}.

10.1371/journal.pone.0003750.t003

###### Significantly differentially regulated transcripts comparing patients with eosinophilic infiltrates to healthy controls.

![](pone.0003750.t003){#pone-0003750-t003-3}

  Probe set                                                                                                             Biological process/Gene title                                                                                                         Gene symbol          Fold change   Parametric p-value
  --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------- ------------- --------------------
  Phosphate transport                                                                                                                                                                                                                                                                           
  212489_at                                                                                                               collagen, type V, alpha 1                                                                                                              COL5A1               2.39           0.0000009
  221729_at                                                                                                               collagen, type V, alpha 2                                                                                                              COL5A2               3.20           0.0001189
  225681_at                                                                                                       collagen triple helix repeat containing 1                                                                                                      CTHRC1               3.25           0.0002197
  230867_at                                                                                                             hypothetical protein LOC131873                                                                                                         LOC131873              2.28           0.0000307
  Signaling pathway                                                                                                                                                                                                                                                                             
  203697_at                                                                                                                frizzled-related protein                                                                                                               FRZB                7.67           0.0004106
  203698_s\_at                                                                                                                                                                                                                                                                        3.02           0.0004541
  Signal transduction                                                                                                                                                                                                                                                                           
  209541_at                                                                                                      insulin-like growth factor 1 (somatomedin C)                                                                                                     IGF1                3.06           0.0000059
  209542_x\_at                                                                                                                                                                                                                                                                        2.51            0.000116
  211577_s\_at                                                                                                                                                                                                                                                                        2.14           0.0001273
  209822_s\_at                                                                                                      very low density lipoprotein receptor                                                                                                        VLDLR                3.35           0.0002441
  Immune response                                                                                                                                                                                                                                                                               
  203828_s\_at                                                                                                         interleukin 32///interleukin 32                                                                                                            IL32                5.45           0.0005892
  211430_s\_at           immunoglobulin heavy locus///immunoglobulin heavy constant gamma 1 (G1m marker)///immunoglobulin heavy constant gamma 2 (G2m marker)///immunoglobulin heavy constant gamma 3 (G3m marker)///immunoglobulin heavy constant mu   <IGHIGHG1IGHG2IGHG3IGHM>      4.37           0.0001606
  221651_x\_at                                                                                        immunoglobulin kappa constant///immunoglobulin kappa variable 1-5                                                                                      IGKC///IGKV1-5           2.21           0.0001881
  Transcription                                                                                                                                                                                                                                                                                 
  214608_s\_at                                                                                                        eyes absent homolog 1 (Drosophila)                                                                                                          EYA1                2.30           0.0001005
  209357_at                                                                                   Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2                                                                                  CITED2               0.34           0.0009738
  227705_at                                                                                                     transcription elongation factor A (SII)-like 7                                                                                                   TCEAL7               2.79            0.000246
  Metabolic process                                                                                                                                                                                                                                                                             
  43427_at                                                                                                            acetyl-Coenzyme A carboxylase beta                                                                                                         ACACB                0.44           0.0002438
  49452_at                                                                                                                                                                                                                                                                            0.39           0.0001128
  224918_x\_at                                                                                                      microsomal glutathione S-transferase 1                                                                                                       MGST1                0.27           0.0003928
  Transport                                                                                                                                                                                                                                                                                     
  202236_s\_at                                                                                      solute carrier family 16 (monocarboxylic acid transporters), member 1                                                                                       SLC16A1               2.74           0.0000816
  239984_at                                                                                                     sodium channel, voltage-gated, type VII, alpha                                                                                                   SCN7A                2.64           0.0005832
  Other functions                                                                                                                                                                                                                                                                               
  205206_at                                                                                                              Kallmann syndrome 1 sequence                                                                                                             KAL1                0.25           0.0004374
  226312_at                                                                                                              TORC2-specific protein AVO3                                                                                                              AVO3                0.47           0.0003421
  227013_at                                                                                                  LATS, large tumor suppressor, homolog 2 (Drosophila)                                                                                                LATS2                0.41           0.0005208
  224842_at                                                                                                            PI-3-kinase-related kinase SMG-1                                                                                                           SMG1                0.39           0.0002757
  202965_s\_at                                                                                                                    calpain 6                                                                                                                      CAPN6                4.00            \<1e-07
  201609_x\_at                                                                                                   isoprenylcysteine carboxyl methyltransferase                                                                                                     ICMT                2.35           0.0007576
  202998_s\_at                                                                                                               lysyl oxidase-like 2                                                                                                                LOXL2                2.03           0.0004611
  209596_at                                                                                                            matrix-remodelling associated 5                                                                                                           MXRA5                4.66           0.0001074
  209398_at                                                                                                                     histone 1, H1c                                                                                                                  HIST1H1C              0.26           0.0007007
  226322_at                                                                                                           ARG99 protein ( Gene name: TMTC1)                                                                                                          ARG99                0.45           0.0002993
  205381_at                                                                                                           leucine rich repeat containing 17                                                                                                          LRRC17               2.60           0.0001683
  219087_at                                                                                                                 asporin (LRR class 1)                                                                                                                 ASPN                5.76            0.000238
  Unknown                                                                                                                                                                                                                                                                                       
  202760_s\_at                                                                                              A kinase (PRKA) anchor protein 2///PALM2-AKAP2 protein                                                                                        AKAP2///PALM2-AKAP2         2.71           0.0000528
  202759_s\_at                                                                                                               PALM2-AKAP2 protein                                                                                                              PALM2-AKAP2             3.29           0.0000042
  226155_at                                                                                                                        KIAA1600                                                                                                                     KIAA1600              0.46           0.0004366
  235022_at                                                                                                          chromosome 18 open reading frame 19                                                                                                        C18orf19              2.46           0.0002359
  229778_at                                                                                                             hypothetical protein MGC10946                                                                                                           MGC10946              2.92           0.0007268
  219525_at                                                                                                             hypothetical protein FLJ10847                                                                                                           FLJ10847              0.42           0.0004347
  211724_x\_at                                                                                                          hypothetical protein FLJ20323                                                                                                           FLJ20323              0.45           0.0003093
  225893_at                                                                                                             clone TESTIS-724 mRNA sequence                                                                                                                                0.41           0.0001744

Genes involved in immune response such as IL-32, IGHG1, and IGKC were upregulated, as well as CAPN6, while those involved in chemotaxis or regulation of the protein kinase B signaling cascade were downregulated in asymptomatic cases comparing with controls.

Validation of microarray data by quantitative RT-PCR {#s3d}
----------------------------------------------------

The main correlation between the two assays is showed in [Figure 2](#pone-0003750-g002){ref-type="fig"}. Real-time PCR was not only used to confirm the abnormal gene expression profiles detected by microarray analysis, but also to better define fold-change variations using a more sensitive approach. This approach showed mean fold changes in expression levels directionally similar to those determined by microarray analysis. Overall, fold change was lower when the microarray approach was used compared to real-time PCR ([Table 2](#pone-0003750-t002){ref-type="table"}).

![Comparison between expression data obtained from microarray experiments and data obtained from quantitative RT-PCR.](pone.0003750.g002){#pone-0003750-g002}

Discussion {#s4}
==========

The main correlation between the two assays, microarrays and quantitative RT-PCR, was high for all genes, indicating a good agreement between both assays for identification of deregulated genes.

On the other hand, by means of the additional supporting process, a high correlation degree among results was shown and it provided more reliability to the final list of genes. Therefore, results of the two machine learning approaches support the degree of relevance of the 74 genes identified.

Calpain 3 was not abnormally regulated in the microarray study (data not shown). While protein analysis usually shows an absence of protein in patients, the microarray data did not reveal a reduction of calpain 3 mRNA indicating that this primary genetic defect cannot be identified by expression profiling. It is worthwhile mentioning that the presence of different missense mutations in most of the patients may explain this observation as well as the variability found in the Western Blot including normal patterns [@pone.0003750-Senz1].

In LGMD2A muscles, genes associated with ECM/membrane-related, cell adhesion genes, muscle development genes, signaling pathway genes, and ubiquitin cycle genes were upregulated ([Table 2](#pone-0003750-t002){ref-type="table"}).

Extracellular matrix {#s4a}
--------------------

The general trend for structural genes to be expressed at higher levels in patients could reflect a general upregulation of structural genes in the mutant muscle, as previously reported for other types of muscular dystrophies [@pone.0003750-vonderHagen1].

It is interesting to note that a large proportion of genes associated to the extracellular matrix were probably upregulated as a result of fibrotic infiltration. These genes include extracellular matrix proteins such as collagen types I and III (the two major collagens in the ECM), cell adhesion proteins such as CD9, CD44, and fibronectin.

SPARC, overexpressed in the fibroblasts of skin biopsy specimens obtained from patients with systemic sclerosis [@pone.0003750-Zhou1], could be the factor involved in the interstitial fibrosis seen in muscles of LGMD2A patients. It is a matricellular glycoprotein that may modulate cell interaction within the ECM by binding to both ECM structural components and growth factors.

Muscle development {#s4b}
------------------

Our results showed that MYH3 (myosin, heavy chain 3, skeletal muscle, embryonic) is highly upregulated in samples from LGMD2A patients. Expression of embryonic myosin heavy chain is a hallmark of muscle regeneration after birth and a characteristic marker of human muscular dystrophies. During normal human development, expression is restricted to the embryonic period of development [@pone.0003750-KarschMizrachi1]. This could indicate a failed muscular regeneration attempt to compensate a downstream injury.

Another upregulated gene is myosin light chain 1 slow A (MLC1SA), a transcriptional regulator promoting muscle cell proliferation expressed in both slow-twitch skeletal muscle and non-muscle tissue. This gene showed a high individual correlation with class phenotype (0.442), and was one of the seven genes included in the CFS output. This fact flawlessly demonstrates its importance not only from an individual point of view, but also because of its potential interactions. MLC1SA is one of the two phosphorylable regulatory light chains forming the myosin complex. Cohen et al [@pone.0003750-Cohen1] found that MLC1SB (Accession N° P09542 in mice) was a substrate for calpain 3. To date, no contractile proteins have been identified as *in vivo* substrates for CAPN3. Identification of MLC1 as a potential substrate for CAPN3 was of interest because, in a previous study, Kramerova et al [@pone.0003750-Kramerova2] demonstrated that CAPN3 regulates sarcomere remodeling by acting upstream of the ubiquitin--proteasome system.

LGMD2A patients showed upregulation of the IGF-1 gene as previously observed in other muscular dystrophies. Normal skeletal muscle is able to efficiently repair itself in response to injury. IGF-1 has been implicated as a factor that may affect many steps in gene expression control, including cell proliferation, differentiation, and degradation processes. IGF-1 is a peptide that has been shown to have anabolic effects on muscle cells. This action can be explained based on the molecular signaling events initiated by its receptor, a tyrosine kinase activated on IGF-1 binding, and transmitted through a cascade of intracellular events, leading to a general increase in protein synthesis [@pone.0003750-Marotta1], [@pone.0003750-Baldwin1].

Integrin β1 binding protein (ITGB1BP2 = melusin), also upregulated in LGMD2A muscles, is present in a costamere-like pattern consisting of two rows flanking a-actinin at Z line. Melusin expression is upregulated during *in vitro* differentiation of the C2C12 murine myogenic cell line, and is regulated during *in vivo* skeletal muscle development [@pone.0003750-Brancaccio1]. Upregulation of the melusin gene may alter a process that is tightly controlled in muscle development, leading to inadequate muscle differentiation and maturation. The generalized inhibition of terminal stages of myogenic differentiation in C3KO myotubes affects at least two events: sarcomere formation and integrin isoform replacement [@pone.0003750-Kramerova3]. During myogenesis, two isoforms of β1 integrin are expressed: β1A is expressed in myoblasts and is downregulated during myogenesis, while β1D appears after fusion and eventually displaces β1A in mature myotubes [@pone.0003750-Belkin1]. Neither β1A nor β1D were cleaved by CAPN3, suggesting that changes in the level of integrin isoforms are not a direct result of calpain 3 absence [@pone.0003750-Kramerova3].

Ubiquitin cycle and protein degradation {#s4c}
---------------------------------------

It is still unclear whether CAPN3 directly cleaves proteins to make them available for ubiquitination or whether the effect of CAPN3 is indirect (i.e. through regulation of other proteins involved in ubiquitination) [@pone.0003750-Kramerova2]. In LGMD2A muscle samples, the HERC1 and ANAPC1 genes involved in the ubiquitin cycle are upregulated, suggesting that their regulation may be under the control of calpain 3.

Moreover, Ono et al [@pone.0003750-Ono3] found proteolysis of proteasome regulatory subunit RPS6A by calpain 3, which may indicate that the ubiquitin-proteasome system is subject to regulation by calpain.

As ubiquitination tags proteins for degradation, decreased ubiquitination may lead to excessive accumulation of the proteins that should otherwise be degraded. This in turn could trigger a cell stress response, one manifestation of which is upregulation of heat shock proteins [@pone.0003750-Kramerova2]. According to the reported data, the DnaJ (Hsp40) homolog, subfamily A member 4 (DNAJA4), that showed upregulation, may regulate the chaperone function of Hsp70 proteins [@pone.0003750-Cyr1].

Signaling pathways {#s4d}
------------------

The protein coded by HERC1, upregulated in LGMD2A patients, has a C-terminal HECT (homologous to E6-AP C-terminus) domain, which suggests that it has an ubiquitin ligase activity.

β-catenin plays a critical role in many cellular and morphogenic processes by performing two distinct functions: in the nucleus, it acts as a mandatory coactivator of TCF/LEF transcription factors in response to Wnt signaling during both embryonic development and adult muscle regeneration, while at the cell membrane, β-catenin associates with the cadherin complex that links adhesion molecules to the cytoskeleton. In both cases, the concentration of β-catenin has been shown to be tightly regulated through ubiquitin-mediated degradation [@pone.0003750-Kramerova3].

Two distinct ubiquitin ligase complexes control β-catenin levels in cytoplasm and at the membrane [@pone.0003750-Wu1]. Ubiquitination and degradation of the cytosolic pool of β-catenin are under the control of Wnt signaling. Degradation of the membrane pool of β-catenin in skeletal muscle is mediated by the Ozz-E3 ubiquitin ligase complex [@pone.0003750-Nastasi1]. Thus, it may be suggested that membrane β-catenin is indirectly regulated by CAPN3. It should also be noted that Trim32, found mutated in limb-girdle muscular dystrophy type 2H, is another putative E3-ubiquitin-ligase [@pone.0003750-Frosk1].

On the other hand, frizzled-related protein (FRZB) is upregulated in LGMD2A muscle samples. It could therefore be hypothesized that β-catenin regulation is also altered at the Wnt signaling pathway, leading to an abnormal myotube fusion or incorrect myogenesis.

Deregulation of mitochondrial genes {#s4e}
-----------------------------------

In our results, the mitochondrial genes found to be deregulated were ALDH2 and PPM2C. ALDH2 was downregulated in patient samples and is implicated in the glycolysis/gluconeogenesis pathway. On the contrary, expression of the PPM2C mitochondrial gene was upregulated in our study. Protein phosphatase 1J (PPM1J_mouse, PP2C family) was found to be an *in vivo* substrate for calpain 3 [@pone.0003750-Cohen1].

In later stages of the disease, the muscle pathology is characterized mainly by the presence of lobulated fibers (LF), which are composed of misaligned myofibrils that form a lobular pattern, in addition to fiber size variation and interstitial fibrosis. Lobulated muscle fibers reflect an abnormal spatial distribution of the intermyofibrillar mitochondria network [@pone.0003750-FigarellaBranger1]. In C3KO mice, abnormal A-bands were seen, suggesting a role for calpain 3 in correct formation of sarcomeres or maintenance of sarcomere alignment [@pone.0003750-Kramerova1].

mRNA expression profiles were specifically altered in LGMD2A muscles with lobulated fibers Keira et al [@pone.0003750-Keira1]. Genes encoding for extracellular matrix (ECM)/membrane-related, cytoskeletal, or sarcomeric proteins were also upregulated in LF muscles.

According to these results, identification of these mitochondrial proteins suggests that CAPN3 may be involved in mitochondrial protein turnover.

Common genes with altered expression in different muscular dystrophies {#s4f}
----------------------------------------------------------------------

According to [Table 2](#pone-0003750-t002){ref-type="table"}, LGMD2A can be characterized as an active fibrotic disease with suppressed muscle regeneration, since LGMD2A cases share upregulation of the extracellular matrix (ECM) components with congenital muscular dystrophy cases and share downregulation of the transcription factors with Duchenne muscular dystrophies.

In muscles from patients with Duchenne muscular dystrophy, upregulated genes were mostly those related to immune response, sarcomeric, ECM, and cell growth, whereas downregulated genes were associated to energy metabolism, transcription/translation, signaling, and proteasomes [@pone.0003750-Noguchi1].

c-fos and c-jun proteins have been described as showing strong cytoplasmic expression related to the degeneration process occurring in Duchenne and Becker muscular dystrophies [@pone.0003750-Oliv1]. However our results contradict the previously published results and they showed a strong downregulation of c-fos and c-jun in our samples.

Recently Gan et al [@pone.0003750-Gan1] reported that Dishevelled (Dvl) and c-Jun form a complex with β-catenin-T-cell factor 4 (TCF-4) on the promoter of Wnt target genes and regulate gene transcription. c-Jun mediates Dvl association with the functional TCF-β-catenin complex and functions as a key component of Wnt signaling *in vivo*. Since genes coding for proteins in this pathway are dysregulated in LGMD2A patients, it may be suggested that the downregulation of c-jun and other transcription factors observed in LGMD2A patients are regulated in an indirect way by calpain 3.

TFRC (transferrin receptor) and VLDLR (very low density lipoprotein receptor) are upregulated in LGMD2A patients as occurred in FSHD muscles [@pone.0003750-Winokur1]. Transferrin is a key myoblast trophic factor, initially promoting myoblast proliferation and subsequently supporting myogenic differentiation. However, TXNIP (thioredoxin-interacting protein) is downregulated in LGMD2A muscles and was also downregulated in FSHD samples [@pone.0003750-Winokur1]. Since TXNIP acts as an oxidative stress mediator, this finding is consistent with the enhanced vulnerability to oxidative stress seen in LGMD2A, as observed in FSHD myoblasts [@pone.0003750-Winokur1]. Many of the genes deregulated in facioscapulohumeral muscular dystrophy (FSHD) are involved in myogenesis, cell differentiation, and cell-cycle control.

According to the available information, it could be suggested that FSHD shared the greatest quantity of differentially expressed genes and the deregulation tendencies (up/downregulation) are the same and in a similar range of variation. However it would be difficult to establish any correlation given that in the FSHD, even in patients with the same deletion fragment, high variability of impairment and of muscle affectation grade is observed. Therefore, the data depend enormously on the place and on the moment that biopsy has been taken.

S100A6 (calcyclin) and S100A8 (calgranulin A), dysregulated in LGMD2A muscles, are involved in various intracellular and extracellular regulatory activities [@pone.0003750-Donato1]. Upregulation of S100A6 expression was seen also in LGMD2B and as in other muscular dystrophies, the structural defect causes a general membrane instability that leads to an altered uptake of calcium ions into the muscle fibers [@pone.0003750-Campanaro1]. Since calpain 3 interacts with dysferlin and AHNAK, a role of calpain 3 in membrane homeostasis has been suggested [@pone.0003750-Huang1], [@pone.0003750-Huang2]. The increased Ca2+ concentration probably influences expression of various signaling molecules whose transcription is sensitive to calcium concentration.

Dysferlin was not abnormally regulated in LGMD2A patients in the microarray study. The value obtained for the expression of the DYSF gene did not fulfil the established criteria to be considered as differently expressed (data not shown).

In this study mRNA levels are analysed, not protein quantities. Even if the protein is reduced in the Western Blot, this reduction may not be regulated at a transcriptional level, it may happen at a post-translation level. Since calpain 3 was shown to be in complex with dysferlin and it has been demonstrated that AHNAK, a novel component of the dysferlin protein complex, serves as a direct substrate of calpain 3 in cell culture, the lack of one of these proteins may justify the reduction of the other.

As described in previous works [@pone.0003750-Campanaro1] while western blotting tests showed a reduction or the absence of dysferlin protein in most LGMD2B patients, the microarray data showed a reduction of dysferlin mRNA for some of the patients analysed. This could be due to the different types of mutations of the gene that affects the translation efficiency of the mRNA or the stability of the protein. Additionally, while protein analysis usually shows an absence of protein in the C57BL/10.SJL-*Dysf* mice, the microarray data did not reveal a reduction of dysferlin mRNA indicating that this primary genetic defect cannot be identified by expression profiling [@pone.0003750-vonderHagen1]. Moreover, it has been observed that neither calpain-3 nor caveolin was consistently reduced in dysferlinopathies.

The vast majority of upregulated genes in Fukuyama-type congenital muscular dystrophy (FCMD) and laminin-a2 deficient congenital muscular dystrophy (MDC1A) encode extracellular matrix components, presumably related to fibrotic change. However, mature muscle components were extremely downregulated in congenital muscular dystrophies [@pone.0003750-Taniguchi1].

Muscle regeneration is also a process that depends on the skeletal muscle basement membrane. Basement membrane is thought to not only maintain cell integrity but also to mediate signal transmission in cell differentiation, growth, attachment, survival, polarity, proliferation, and apoptosis [@pone.0003750-Campbell1], [@pone.0003750-Ervasti1]. It is hypothesized that upregulation of ECM genes might arise from signal transduction defects due to basement membrane dysfunction. It is possible that muscle fibers keep high transcription levels of ECM to create basement membrane components [@pone.0003750-Taniguchi1].

Costameric proteins can interact with many components of both the sarcolemma and cytoskeleton. Different publications support a role for the costamere/Z-disk axis in mechanotransduction, the dynamic process through which mechanical stimuli are sensed by muscle cells and converted into biochemical responses [@pone.0003750-Ervasti1].

Based on our results and since collagens, melusin and fibronectin, were deregulated, we may hypothesize that upregulation of ECM genes found in LGMD2A patients may result from signal transduction defects due to basement membrane dysfunction. Calpain 3 recognizes a wide range of substrates, including cytoskeletal proteins and myofibrillar proteins [@pone.0003750-Cohen1], [@pone.0003750-Ono3]. These cytoskeletal proteins and matrix proteins contribute to cell shape, mechanical resistance, and morphological integrity of muscle cells, and are part of a complex network of filaments and tubules that transmit mechanical and chemical stimuli between cells. The cytoskeleton is not only involved in cell stability and integrity, but also plays a significant role in signal transmission from the cell membrane to the nucleus.

LGMD2A and eosinophilic infiltrations {#s4g}
-------------------------------------

Presence of eosinophilic cells has recently been detected in muscle tissue from patients with mutations in the CAPN3 gene [@pone.0003750-Krahn1].

In our study, IL-32 was upregulated in LGMD2A patients with eosinophilic infiltrates ([Table 3](#pone-0003750-t003){ref-type="table"}). Although IL-32 does not share sequence homology with known cytokine families, IL-32 induces various cytokines, human TNFα, and IL-8 in THP-1 monocytic cells. IL-32 activates typical cytokine signal pathways of nuclear factor-kappa B (NF-κB) and p38 mitogen-activated protein kinase [@pone.0003750-Kim1]. The neutrophil-derived proteinase 3 (PR3) was identified as a putative IL-32 receptor [@pone.0003750-Dinarello1], supporting the possibility that IL-32 upregulation in muscle may be chemoattractant for eosinophilic cells.

Eosinophilia has also been reported as a prominent feature of the necrotic phase in dystrophin-deficient mdx mice. This study suggested that eosinophilia was promoted by at least perforin-dependent cytotoxicity of effector T cells and T-cell production of interleukin-5 (IL-5) [@pone.0003750-Cai1]. However these authors concluded that some eosinophilia of mdx muscle is independent from perforin-mediated processes and that it may be suggested that a similar mechanism of calpain 3 could act in this process.

Inflammatory features may be seen in some muscular dystrophies, such as facioscapulohumeral muscular dystrophy [@pone.0003750-Arahata1] and dysferlinopathies [@pone.0003750-Gallardo1]. Moreover, a Becker muscular dystrophy presenting eosinophilic inflammatory myopathy was described by Weinstock et al [@pone.0003750-Weinstock1].

Although the comparison between gene expression profiles between LGMD2A with and without eosinophilia would be interesting, it was not possible to perform. The methods used needed a higher quantity of samples to obtain significant results. Moreover, when a PCA plot was performed for LGMD2A patients only (including cases with and without eosinophilia), no different groups were created and this may be due to the low sample number too.

It seems that the comparison between asymptomatic patients with eosinophilia with control samples is more indicated to shed some light onto the initial mechanism that triggers the eosinophilic cell attraction to muscle. The comparison between asymptomatic patients and controls allows a clearer view due to a lower interfering expression variation.

In a first approach asymptomatic cases were considered as affected and were included into the patient group in the general analysis. These cases were included in the affected group due to their abnormal muscle biopsy pattern. Additionally reinforcing this decision, the PCA plots clustered together the LGMD2A case with or without eosinophilia.

Finally in an additional analysis, however, it was decided to consider them as a different group compared to the controls in order to obtain information about eosinofilic attraction in the early stage of the disease.

Conclusions {#s4h}
-----------

In conclusion, upregulated genes were mostly those related to extracellular matrix, cell adhesion, sarcomeric proteins, and signal transduction. It is therefore suggested that different proteins located at or participating in the costameric region are involved in processes regulated by calpain 3 during skeletal muscle development. Upregulation of these proteins may indicate a compensatory attempt of the muscle, and since most of these genes are also upregulated in other dystrophic processes, upregulation might be relatively nonspecific.

It was also found that genes participating in the ubiquitin proteasome degradation pathway are deregulated in LGMD2A patients, which suggests that regulation of this pathway may be under the control of calpain 3 activity.

Finally, the upregulation of IL-32 and immunoglobulin genes may cause the eosinophil chemoattraction observed in the inflammatory findings in presymptomatic stages. This upregulation seems to disappear when the disease progresses. However, they might be quite specific markers for the disease.

Though samples taken from different muscles could add variability to the results of the expression array analysis, correlation of the results with the quantitative RT-PCR results gave strength to the findings. Gene expression profiling is presented as a useful approach to mine new data and hopefully open new perspectives for muscular disorders, shedding some light on identification of novel therapeutic targets for limb-girdle muscular dystrophies.

Looking ahead, each of these methods should be individually analyzed in the animal model and in cell models.

This analysis gives a total of 24 genes that may be considered as potential diagnostic or evolutionary biomarkers of the disease. However, this question will not be solved until the predictive value of these markers is proved in a series of patients with different evolutive status and secondly until the consistency of the results in different muscles and different laboratories is proved.
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